Comparison of Mid-term angiographic outcomes of second generation drug-eluting-stent

Second versus first generation drug eluting stents during stent overexpansion.

Comparison of long-term angiographic follow-up after sirolimus-eluting stent and bare-metal stent implantation.

BACKGROUND The sirolimus-eluting stent (SES) has dramatically reduced the rate of restenosis in comparison to that with the bare-metal stent (BMS). In previous studies, the minimal luminal diameter (MLD) of lesions treated with a BMS was shown to improve from 6 months to 1 year. METHODS To evaluate 6-month and 1-year outcomes, angiographic follow-up data were analyzed for 285 patients (451 le...

In-Stent Restenosis Exacerbated by Drug-Induced Severe Eosinophilia after Second-Generation Drug-Eluting Stent Implantation

BACKGROUND In-stent restenosis (ISR) is still a recognized clinical problem in the era of drug-eluting stent (DES). Some previous studies have suggested that circulating eosinophils play an important role in both restenosis and thrombosis after DES implantation. However, the contribution of eosinophils to the pathogenesis of ISR has not yet been concisely clarified. CASE REPORT We present the...

Overview of Intracoronary Brachytherapy for in-Stent Restenosis of a Drug-Eluting Stent

Percutaneous coronary intervention with stenting is considered recently as the most common procedure for the treatment of symptomatic coronary. The article reviewed 41 studies published during 1997-2019 on intracoronary brachytherapy for in-stent restenosis of a drug-eluting stent. Intracoronary radiation therapy was finally confirmed in the setting of in-stent restenosis using as adjunctive th...

Acute stent recoil from aggressive post-dilation of a second-generation drug-eluting stent.